The Food and Drug Administration (FDA) has approved Kadcyla (ado-trastuzumab emtansine; Genentech) for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual ...

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company ...

As biosimilar competition to Herceptin ramps up, Roche is looking to bolster its position in HER2-positive breast cancer with a new indication for Kadcyla. The Swiss pharma firm has announced that it ...

The approval is based on data showing Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer The ...

Roche’s breast cancer drug Kadcyla is set for regular NHS funding in England after the company finally agreed a deal with NICE. The row over Kadcyla has lasted three years, and has been one of the ...

All of the women in the study had progressed on two or more HER2-targeted therapies, including Herceptin (trastuzumab) and Tykerb (lapatinib). Kadcyla (ado-trastuzumab emtansine; T-DM1) reduced the ...

Roche’s Kadcyla needs some oomph, and the Swiss drugmaker’s new data might just do the trick. The company is teeing up a new filing for its next-generation breast cancer drug, hoping to gin up more ...

– Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date – We apologize, but this video has failed to load. Try ...

The great Welsh politician Aneurin Bevan, main architect of the NHS, famously said "No society can legitimately call itself civilized if a sick person is denied medical aid because of a lack of means.

Britain’s National Institute for Health and Care Excellence (NICE) has followed through on its Kadcyla objections and has said Roche’s breast cancer drug will remain off the National Health Service’s ...

Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date 1,2 Long-term data also showed continued benefit in invasive ...

– Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date – – Long-term data also showed continued benefit in invasive ...